A humanized antibody against human cytomegalovirus (CMV) gpUL75 (gH) for prophylaxis or treatment of CMV infections

Journal of Infectious Diseases

Volumn 176, Issue 1, 1997, Pages 59-68

  Hamilton, Anita A ^b   Manuel, Donna M ^c   Grundy, Jane E ^a   Turner, Andrew J ^d   King, Susan I ^b   Adair, John R ^e   White, Patricia ^b   Carr, Frank J ^b   Harris, William J ^f  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Eclagen Ltd   (United Kingdom)

^c MEDIMMUNE LTD   (United Kingdom)

^d Castle Court   (United Kingdom)

^e Axis Genetics plc   (United Kingdom)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; VIRUS PROTEIN;

ANTIGEN BINDING; ARTICLE; CYTOMEGALOVIRUS INFECTION; GENE SEQUENCE; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN CONSTANT REGION; INFECTION PREVENTION; PRIORITY JOURNAL; PROTEIN INTERACTION;

EID: 0030948785     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514040     Document Type: Article

References (15)

1. Grundy JE, Super M, Sweny P, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988;2:132-5.
2. Grundy JE. Virologic and pathogenic aspects of cytomegalovirus infection. Rev Infect Dis 1990;12(suppl 7):S711-9.
3. Grundy JE. Cytomegalovirus pathogenesis in transplantation. Can J Infect Dis 1993;4(suppl X):1-7.
4. Chee MS, Bankier AT, Beck S, et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 1990;154:126-69.
5. Britt WJ. Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 1984;135:369-78.
6. Kari B, Goertz R, Gehrz R. Characterization of cytomegalovirus glycoproteins in a family of complexes designated gC-II with murine monoclonal antibodies. Arch Virol 1990;112:55-65.
7. Rasmussen LE, Nelson RM, Kelsall DC, Merigan TC. Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc Natl Acad Sci USA 1984;81:876-80.
8. Kaye JF, Gompels UA, Minson AC. Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product. J Gen Virol 1992;73:2693-8.
9. Gonczol E, deTaisne C, Hirka G, et al. High expression of human cytomegalovirus (HCMV) gB protein in cells infected with a vaccinia gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 1991;9:631-97.
10. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 1990;64:1079-85.
11. Rasmussen L, Matkin C, Spaete R, Pachl C, Merigan TC. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 1991;164:835-42.
12. Rasmussen L. Progress in the development of a human cytomegalovirus glycoprotein subunit vaccine. In: Michelson S, Plotkin SA, eds. Exerpta Medica international conference series (no. 1032): multidisciplinary approach to understanding cytomegalovirus disease. Amsterdam: Elsevier Science Publishers, 1993;311-20.
13. Snydman D, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317;1049-54.
14. Snydman DR. Cytomegalovirus immunoglobulin in the prevention and treatment of cytomegalovirus disease. Rev Infect Dis 1990;12(suppl 7); S839-48.
15. Weimar W, Metselaar HJ, Balk AHMM, Mochtar B, Rothbarth PH, Jeekel J. Passive immunization to prevent cytomegalovirus disease after kidney and heart transplantation. Transplant Proc 1990;22:229-32.